Literature DB >> 25510269

The role of mutations in epigenetic regulators in myeloid malignancies.

Brittany A Woods1, Ross L Levine.   

Abstract

Over the past decade, genomic studies have identified a number of novel and recurrent somatic mutations that affect epigenetic patterning in patients with myeloid malignancies, including myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia. Many of these mutations occur in genes with established roles in the regulation and maintenance of DNA methylation and/or chromatin modifications in hematopoietic stem/progenitor cells. Subsequent genetic and functional studies have revealed that these mutations affect epigenetic patterning in myeloid diseases. In this review, we discuss historical and recent studies implicating epigenetic modifiers in the development and evolution of the various myeloid malignancies and discuss how this knowledge has and will lead to future clinical and biologic insights.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  chromatin regulation; genomics; myelopoiesis

Mesh:

Year:  2015        PMID: 25510269     DOI: 10.1111/imr.12246

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  22 in total

Review 1.  Deubiquitinases: Pro-oncogenic Activity and Therapeutic Targeting in Blood Malignancies.

Authors:  Blanca T Gutierrez-Diaz; Wei Gu; Panagiotis Ntziachristos
Journal:  Trends Immunol       Date:  2020-03-02       Impact factor: 16.687

Review 2.  Targeting EZH2 and PRC2 dependence as novel anticancer therapy.

Authors:  Bowen Xu; Kyle D Konze; Jian Jin; Gang Greg Wang
Journal:  Exp Hematol       Date:  2015-05-28       Impact factor: 3.084

3.  When cancer and immunology meet.

Authors:  Martin Carroll
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

4.  TET2, DNMT3A, IDH1, and JAK2 Mutation in Myeloproliferative Neoplasms in southern Iran.

Authors:  E Abedi; M Ramzi; M Karimi; R Yaghobi; H Mohammadi; E Bayat; M Moghadam; F Farokhian; M Dehghani; H A Golafshan; S Haghpanah
Journal:  Int J Organ Transplant Med       Date:  2021

Review 5.  IDH2: A novel biomarker for environmental exposure in blood circulatory system disorders.

Authors:  Ya Qi Gong; Shuang Wei; Yuan Yun Wei; Yong Lin Chen; Jian Cui; Yue Qiu Yu; Xiang Lin; Hong Xia Yan; Hui Qin; Lan Yi
Journal:  Oncol Lett       Date:  2022-06-24       Impact factor: 3.111

6.  KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice.

Authors:  Yue Wei; Hong Zheng; Naran Bao; Shan Jiang; Carlos E Bueso-Ramos; Joseph Khoury; Caleb Class; Yue Lu; Kevin Lin; Hui Yang; Irene Ganan-Gomez; Daniel T Starczynowski; Kim-Anh Do; Simona Colla; Guillermo Garcia-Manero
Journal:  Blood Adv       Date:  2018-10-09

7.  LINC01128 resisted acute myeloid leukemia through regulating miR-4260/NR3C2.

Authors:  Haixia Li; Xuefei Tian; Paoqiu Wang; Jihong Hu; Rong Qin; Ronghua Xu; Kai Liu; Jingquan Hao; Nie Tian
Journal:  Cancer Biol Ther       Date:  2020-04-26       Impact factor: 4.742

Review 8.  Clonal evolution in leukemia.

Authors:  Adolfo A Ferrando; Carlos López-Otín
Journal:  Nat Med       Date:  2017-10-06       Impact factor: 53.440

Review 9.  Epigenetics in Cancer: A Hematological Perspective.

Authors:  Maximilian Stahl; Nathan Kohrman; Steven D Gore; Tae Kon Kim; Amer M Zeidan; Thomas Prebet
Journal:  PLoS Genet       Date:  2016-10-10       Impact factor: 5.917

Review 10.  Epigenetics of hematopoiesis and hematological malignancies.

Authors:  Deqing Hu; Ali Shilatifard
Journal:  Genes Dev       Date:  2016-09-15       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.